English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the coronavirus disease 2019 (COVID-19), is a new ribonucleic acid virus strain from the Coronaviridae family [1]. From December 2019 to June 2020, the COVID-19 pandemic included over 7.6 million confirmed cases in 216 countries, and over 427,000 deaths [2]. Acute respiratory distress syndrome (ARDS) is one of the most severe complications of COVID-19 [3]. Based on autopsy studies, the ARDS associated with COVID-19 has distinct features — lung damage is consistent with complement-mediated microvascular injury consisting of diffuse microthrombosis and hemorrhage, whereas the hallmarks of classic ARDS with alveolar damage and hyaline membranes are not prominent [4]. Microvascular injury is typically not accompanied by gross pulmonary thromboembolism and parenchymal inflammation [5]. In addition, acro-ischemia including finger/ toe cyanosis, skin bullae and dry gangrene were prodromal or early symptoms of COVID-19 [6, 7], confirming skin damage patterns consistent with microvascular thrombosis. In fact, the cutaneous manifestations are present in up to 20% of patients with COVID-19 and has been classified into five clinical patterns, with pseudo-chilblain being the most, and livedo or necrosis — the least frequent [8]. Thus, microvascular thrombosis seems to be one of the main pathological findings in COVID-19 patients [9, 10]. In addition to respiratory disease, cardiovascular complications are rapidly emerging as a key threat in COVID-19 [11]. In a recent metaanalysis of 8 studies from China including 46,248 infected patients, 7% of patients experienced myocardial injury (22% of these were critically ill), as evidenced by elevated cardiac troponin [12]. Noteworthy, patients with myocardial injury had higher in-hospital mortality (37.5%) than patients with cardiovascular disease (CVD) but without myocardial injury (13.3%), or patients without CVD (7.6%). Moreover, if myocardial injury was present in patients with preexisting CVD, the mortality increased even more (69.4%) [13]. Clearly,

Impaired microcirculation function in COVID-19 and implications for potential therapies.